Veterinary Active Pharmaceutical Ingredients Manufacturing Market Report 2026

Veterinary Active Pharmaceutical Ingredients Manufacturing Market Overview

• Veterinary Active Pharmaceutical Ingredients Manufacturing market size has reached to $8.03 billion in 2025 • Expected to grow to $12.06 billion in 2030 at a compound annual growth rate (CAGR) of 8.5% • Growth Driver: Rising Zoonotic Disease Threats Drive Veterinary API Manufacturing Market • Market Trend: Major Companies Invest In Veterinary API Manufacturing Plants For Market Edge • North America was the largest region in 2025.

What Is Covered Under Veterinary Active Pharmaceutical Ingredients Manufacturing Market?

Veterinary active pharmaceutical Ingredients (APIs) manufacturing refers to the process of producing chemical compounds that are biologically active and used in the formulation of veterinary medicines. These APIs are essential for treating diseases and managing health in animals, including livestock and pets. The manufacturing process ensures the quality, safety, and efficacy of the medications that improve animal welfare and health outcomes. The main products of veterinary active pharmaceutical ingredients manufacturing are anti-infectives, vaccines, and NSAIDs. Chemical-based API refers to the active ingredients of pharmaceutical medicine that have the desired impact on the body in order to cure a disease. The various service types involved are in-house and contract outsourcing, and various synthetic types involve chemical based API, biological API, and highly potent API.

What Is The Veterinary Active Pharmaceutical Ingredients Manufacturing Market Growth Forecast?

The veterinary active pharmaceutical ingredients manufacturing market size is expected to see strong growth in the next few years. It will grow to $12.06 billion in 2030 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period can be attributed to adoption of biological and recombinant apis, growth in contract manufacturing services, rising demand for highly potent apis, regulatory support for veterinary pharmaceutical production, increasing focus on vaccine api innovations. Major trends in the forecast period include growth of contract manufacturing for veterinary apis, development of highly potent apis, expansion of in-house api production capabilities, increasing focus on anti-infective and antiparasitic apis, innovation in vaccine api formulations.

Global Veterinary Active Pharmaceutical Ingredients Manufacturing Market Segmentation

1) By Product: Antiparasitic, Anti-Infectives, Vaccines, NSAIDs 2) By Service Type: In House, Contract Outsourcing 3) By Synthesis Type: Chemical Based API, Biological API, Highly Potent API Subsegments: 1) By Antiparasitic: Endectocides, Anthelmintics, Antiprotozoals 2) By Anti-Infectives: Antibiotics, Antifungals, Antivirals 3) By Vaccines: Inactivated Vaccines, Live Attenuated Vaccines, Recombinant Vaccines 4) By Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Non-Selective NSAIDs, COX-2 Inhibitors

What Is The Driver Of The Veterinary Active Pharmaceutical Ingredients Manufacturing Market?

The increasing prevalence of zoonotic diseases is expected to propel the growth of the veterinary active pharmaceutical ingredients manufacturing market going forward. A zoonotic disease, also known as zoonosis, is an infectious disease that can be transmitted naturally from animals to humans or from humans to animals. Zoonotic diseases are rising because increased human–animal interaction creates more opportunities for pathogens to spread from animals to people and establish new infections. Veterinary APIs are used in the development of vaccines that can prevent the spread of zoonotic diseases from animals to humans. The use of veterinary APIs can also help prevent antibiotic resistance, which is a major concern in the treatment of zoonotic diseases. For instance, in February 2023, according to the Council on Foreign Relations (CFR), a US-based independent, nonpartisan member organization, think tank, and publisher, up to 75% of newly discovered or emerging infectious diseases (EIDs) and 60% of recognized infectious diseases had zoonotic origins. Worldwide, zoonoses cause 2.7 million human fatalities and 2.5 billion episodes of disease in people each year. Therefore, the increasing prevalence of zoonotic diseases is driving the growth of the veterinary active pharmaceutical ingredients manufacturing industry.

Key Players In The Global Veterinary Active Pharmaceutical Ingredients Manufacturing Market

Major companies operating in the veterinary active pharmaceutical ingredients manufacturing market are Alivira Animal Health Limited, Excel Industries Limited, Ofichem Group B.V., Jiangsu Lingyun Pharmaceutical Co. Ltd., SUANFARMA S.A., NGL Fine-Chem Limited, FIS - Fabbrica Italiana Sintetici S.p.A., Lupin Limited, Aurobindo Pharma Limited, Saneca Pharmaceuticals AS, Neuland Laboratories Limited, Divi's Laboratories Limited, Zoetis Inc., Grupo Indukern S.L., Sequent Scientific Limited, Chempro Pharma Private Limited, AMGIS Lifescience Ltd., Huvepharma AD, Vetpharma Animal Health S.L., Qilu Pharma Spain S.A., INDUKERN Chemie AG, Chemopharma S.A., Norbrook Laboratories Limited, Ceva Santé Animale S.A., Vetoquinol S.A., Virbac S.A.

Global Veterinary Active Pharmaceutical Ingredients Manufacturing Market Trends and Insights

Major companies operating in the veterinary active pharmaceutical ingredient manufacturing market are focused on introducing manufacturing plants for APIs to gain a competitive edge in the market. Manufacturing plants for veterinary APIs are facilities that produce active pharmaceutical ingredients used in the formulation of veterinary drugs. For instance, in October 2023, Stallen South Asia Private Limited, an India-based animal health company, launched, unveiled, and started operations at a new veterinary API facility for Halquinol, a non-antibiotic growth promoter belonging to a group of hydroxyquinolines. It is a combination of 5-chloro-8-hydroxyquinoline, 5,7-dichloro-8-hydroxyquinoline, and 7-chloro-8-hydroxyquinoline. Produced products include Halquinol 98%, which is manufactured in accordance with British Pharmacopeia 1980 (BP 80) guidelines. In addition to the more typical 60% and 12%, Stallenis is able to sell 98% as a chemical API used in veterinary formulations and feed additives. Stallen wants to lessen the reliance on goods coming from China for the animal health industry by gradually introducing a wide range of APIs from this plant.

What Are Latest Mergers And Acquisitions In The Veterinary Active Pharmaceutical Ingredients Manufacturing Market?

In May 2024, Veterinary Pharmacy Corporation, a US–based provider of veterinary pharmacy products and animal health services, acquired Diamond Animal Health Inc. for an undisclosed amount. With this acquisition, Veterinary Pharmaceutical Solutions expanded its contract manufacturing and pharmaceutical development capabilities in the animal health space, enhancing its manufacturing footprint and broadening its portfolio of active pharmaceutical ingredients and biologics for veterinary applications. Diamond Animal Health Inc. is a US-based provider of contract manufacturing, research and development, and regulatory services for animal pharmaceuticals and vaccines that supports API production and formulation for livestock and companion animals.

Regional Outlook

North America was the largest region in the veterinary active pharmaceutical ingredients manufacturing market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Veterinary Active Pharmaceutical Ingredients Manufacturing Market?

The veterinary active pharmaceutical ingredients manufacturing market consists of revenues earned by entities by biologics and bulk drugs that are used to create components in medications which are responsible for the positive veterinary health impacts. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.